LeMaitre Vascular saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 63 to 71.
This unique rating tracks market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks compares to other publicly traded companies.
Decades of market research reveals that the best stocks typically have an RS Rating north of 80 in the early stages of their moves. See if LeMaitre Vascular can continue to rebound and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
LeMaitre Vascular is working on a consolidation with a 109.58 entry. See if it can break out in volume at least 40% above average.
The company reported 29% EPS growth last quarter, while sales growth came in at 14%. The next quarterly numbers are expected on or around May 1.
LeMaitre Vascular earns the No. 12 rank among its peers in the Medical-Products industry group. Boston Scientific, Pro-Dex and Axogen are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
